Building Robust Preclinical Development Pathways to Select Predictive Animal Models & Define Translational Endpoints
- Selecting fit-for-purpose animal models that reflect disease relevance, biodistribution, and immunological response to exosome-based interventions
- Establishing translational pharmacology frameworks linking dose, exposure, and functional response across in vitro and in vivo systems
- Integrating safety pharmacology, toxicology, and biodistribution studies to de-risk first in-human clinical trial design